TY - JOUR
T1 - Prevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check
T2 - A prospective cohort study
AU - Re-Imagine Study group
AU - Moore, Caroline M.
AU - Frangou, Elena
AU - McCartan, Neil
AU - Santaolalla, Aida
AU - Kopcke, Douglas
AU - Brembilla, Giorgio
AU - Hadley, Joanna
AU - Giganti, Francesco
AU - Marsden, Teresa
AU - Hemelrijck, Mieke Van
AU - Gong, Fiona
AU - Freeman, Alex
AU - Haider, Aiman
AU - Tuck, Steve
AU - Pashayan, Nora
AU - Callender, Thomas
AU - Green, Saran
AU - Brown, Louise C.
AU - Punwani, Shonit
AU - Emberton, Mark
AU - Moore, Caroline M.
AU - Emberton, Mark
AU - Ahmed, Hashim U.
AU - Moore, Caroline M.
AU - Hemelrijck, Mieke Van
AU - Punwani, Shonit
AU - Rodriguez-Justo, Manuel
AU - Attard, Gerhardt
AU - Brown, Louise
AU - Frangou, Elena
AU - Brew-Graves, Chris
AU - Coolen, Ton
AU - Tuck, Steve
AU - Olalla, Aida Santa
AU - Moss, Charlotte
AU - Green, Saran
AU - McCartan, Neil
AU - Clow, Rosie
AU - Corbett, Ged
AU - Wingate, Anna
AU - Marsden, Teresa
AU - Hadley, Joanna
AU - Akbar, Fatima
AU - Pervez, Hina
AU - Thakali, Suparna
AU - Henderson, Ashling
AU - Tekin, Dizem
AU - Brembilla, Giorgio
AU - Syer, Tom
AU - Kaplan, Richard
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.
PY - 2023/8/21
Y1 - 2023/8/21
N2 - Objective In men with a raised prostate-specific antigen (PSA), MRI increases the detection of clinically significant cancer and reduces overdiagnosis, with fewer biopsies. MRI as a screening tool has not been assessed independently of PSA in a formal screening study. We report a systematic community-based assessment of the prevalence of prostate MRI lesions in an age-selected population. Methods and analysis Men aged 50-75 were identified from participating general practice (GP) practices and randomly selected for invitation to a screening MRI and PSA. Men with a positive MRI or a raised PSA density (≥0.12 ng/mL2) were recommended for standard National Health Service (NHS) prostate cancer assessment. Results Eight GP practices sent invitations to 2096 men. 457 men (22%) responded and 303 completed both screening tests. Older white men were most likely to respond to the invitation, with black men having 20% of the acceptance rate of white men. One in six men (48/303 men, 16%) had a positive screening MRI, and an additional 1 in 20 men (16/303, 5%) had a raised PSA density alone. After NHS assessment, 29 men (9.6%) were diagnosed with clinically significant cancer and 3 men (1%) with clinically insignificant cancer. Two in three men with a positive MRI, and more than half of men with clinically significant disease had a PSA <3 ng/ mL. Conclusions Prostate MRI may have value in screening independently of PSA. These data will allow modelling of the use of MRI as a primary screening tool to inform larger prostate cancer screening studies.
AB - Objective In men with a raised prostate-specific antigen (PSA), MRI increases the detection of clinically significant cancer and reduces overdiagnosis, with fewer biopsies. MRI as a screening tool has not been assessed independently of PSA in a formal screening study. We report a systematic community-based assessment of the prevalence of prostate MRI lesions in an age-selected population. Methods and analysis Men aged 50-75 were identified from participating general practice (GP) practices and randomly selected for invitation to a screening MRI and PSA. Men with a positive MRI or a raised PSA density (≥0.12 ng/mL2) were recommended for standard National Health Service (NHS) prostate cancer assessment. Results Eight GP practices sent invitations to 2096 men. 457 men (22%) responded and 303 completed both screening tests. Older white men were most likely to respond to the invitation, with black men having 20% of the acceptance rate of white men. One in six men (48/303 men, 16%) had a positive screening MRI, and an additional 1 in 20 men (16/303, 5%) had a raised PSA density alone. After NHS assessment, 29 men (9.6%) were diagnosed with clinically significant cancer and 3 men (1%) with clinically insignificant cancer. Two in three men with a positive MRI, and more than half of men with clinically significant disease had a PSA <3 ng/ mL. Conclusions Prostate MRI may have value in screening independently of PSA. These data will allow modelling of the use of MRI as a primary screening tool to inform larger prostate cancer screening studies.
UR - http://www.scopus.com/inward/record.url?scp=85173255780&partnerID=8YFLogxK
U2 - 10.1136/bmjonc-2023-000057
DO - 10.1136/bmjonc-2023-000057
M3 - Article
AN - SCOPUS:85173255780
SN - 2752-7948
VL - 2
JO - BMJ Oncology
JF - BMJ Oncology
IS - 1
M1 - e000057
ER -